Article
CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
British journal of cancer - 1 Sept 2021
Tariq Muhammad Usama, Furqan Muhammad, Parveen Hira, Ullah Rahim, Muddassar Muhammad, Saleem Rahman Shah Zaib, Bavetsias Vassilios, Linardopoulos Spiros, Faisal Amir
Abstract excerpt
BACKGROUND: Activating mutations in the Fms-like tyrosine kinase 3 (FLT3) are among the most prevalent oncogenic mutations in acute myeloid leukaemia. Inhibitors selectively targeting FLT3 kinase have shown promising clinical activity; their success in the clinic, however, has been limited due to the emergence of acquired resistance. METHODS: CCT245718 was identified and characterised as a dual Aurora A/FLT3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.